AMPHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Amphastar Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$26.14+0.27 (+1.04%)
Close on Oct 19, 2026
- Market cap
- $1.16B
- P/E (TTM)
- 15.4
- Dividend yield
- –
Amphastar Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Amphastar Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $1.11B | $164.85M |
| Enterprise Value | $1.43B | $87.06M |
| PE Ratio | 15.38 | 19.63 |
| PS Ratio | 1.52 | 3.60 |
| P/FCF Ratio | 7.27 | 17.44 |
| P/OCF Ratio | 6.02 | 13.32 |
Enterprise value
| Measure | Amphastar Pharmaceuticals | Industry median |
|---|---|---|
| EV / Sales | 1.96 | 2.43 |
| EV / EBITDA | 12.55 | 14.69 |
| EV / EBIT | 12.55 | 18.47 |
| EV / FCF | 9.38 | 20.97 |
Income (trailing twelve months)
| Measure | Amphastar Pharmaceuticals | Industry median |
|---|---|---|
| Revenue | $730.02M | $57.94M |
| Gross Profit | $348.11M | $90.47M |
| Operating Income | $114.29M | -$21.44M |
| Pretax Income | $102.02M | -$14.45M |
| Net Income | $78.55M | -$22.46M |
| EBITDA | $114.29M | -$16.91M |
| EPS (Diluted) | $1.70 | -$0.83 |
Margins
| Measure | Amphastar Pharmaceuticals | Industry median |
|---|---|---|
| Gross Margin | 47.7% | 52.3% |
| Operating Margin | 15.7% | -44.5% |
| Pretax Margin | 14.0% | -13.0% |
| Profit Margin | 10.8% | -39.2% |
| EBITDA Margin | 15.7% | -31.3% |
| FCF Margin | 20.9% | -8.85% |
Returns
| Measure | Amphastar Pharmaceuticals | Industry median |
|---|---|---|
| Return on Assets (ROA) | 4.68% | -41.0% |
| Return on Capital Employed (ROCE) | 7.72% | -37.8% |
Growth
| Measure | Amphastar Pharmaceuticals | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 1.02% | 6.01% |
| Net Income Growth (YoY) | -41.7% | -37.7% |
| EPS Growth (YoY) | -36.3% | -29.2% |
| FCF Growth (YoY) | 36.3% | 2.34% |
| Revenue Growth (3Y CAGR) | 13.0% | 2.25% |
| Revenue Growth (5Y CAGR) | 15.5% | 6.42% |
| EPS Growth (3Y CAGR) | 5.27% | -0.17% |
| EPS Growth (5Y CAGR) | 132.3% | 3.77% |
Balance sheet
| Measure | Amphastar Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $290.12M | $62.42M |
| Total Debt | $612.05M | $120.13M |
| Net Cash (Debt) | -$321.93M | $15.68M |
| Net Cash Per Share | -$7.57 | $0.66 |
| Working Capital | $367.75M | $75.77M |
Financial position
| Measure | Amphastar Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 2.40 | 3.30 |
| Quick Ratio | 1.65 | 2.39 |
| Debt / EBITDA | 5.36 | 3.35 |
| Debt / FCF | 4.00 | 5.05 |
| Net Debt / EBITDA | 2.82 | 2.22 |
| Interest Coverage | 4.37 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Amphastar Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | $184.61M | -$12.35M |
| Capital Expenditures | -$31.72M | -$1.06M |
| Free Cash Flow | $152.89M | -$20.28M |
| FCF Per Share | $3.59 | -$0.42 |
Efficiency
| Measure | Amphastar Pharmaceuticals | Industry median |
|---|---|---|
| Asset Turnover | 0.43 | 0.38 |
| Inventory Turnover | 2.06 | 2.67 |
| Revenue Per Employee | $4.48M | $398.96K |
| Profits Per Employee | $481.88K | -$703.34K |
| Employee Count | 163 | 74 |
Dividends and yields
| Measure | Amphastar Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | 7.06% | -22.7% |
| FCF Yield | 13.8% | -9.07% |
| Buyback Yield | 9.00% | -0.73% |
| Shareholder Yield | 9.00% | 0.00% |
Shares
| Measure | Amphastar Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 42,537,900 | 58,179,650 |
| Shares Change (YoY) | -7.79% | 11.1% |
| Shares Change (QoQ) | -4.71% | 0.54% |
| Float | 26,080,500 | 49,173,100 |
| Shares Held by Insiders | 38.7% | 11.6% |
| Shares Held by Institutions | 66.6% | 59.4% |
Taxes
| Measure | Amphastar Pharmaceuticals | Industry median |
|---|---|---|
| Income Tax | $23.48M | $91.50K |
| Effective Tax Rate | 23.0% | 20.6% |
Scores
| Measure | Amphastar Pharmaceuticals | Industry median |
|---|---|---|
| Altman Z-Score | 2.14 | -0.24 |
| Piotroski F-Score | 6 | 4 |
Calculated by StockData from Amphastar Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.